{"product_id":"cencora-five-forces-analysis","title":"Cencora Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCencora faces moderate buyer power, concentrated supplier relationships, regulatory pressures, and evolving substitute threats that shape its margins and strategic choices; competitive rivalry is intense as players optimize scale and services. This snapshot only scratches the surface—unlock the full Porter's Five Forces Analysis to explore Cencora’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of pharmaceutical manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary suppliers for Cencora are large pharmaceutical companies, and as of late 2025 a handful of global players supply roughly 60–70% of top-selling brand drugs, giving them strong pricing power. These manufacturers can dictate contract terms and rebates for high-demand medications, limiting Cencora’s leverage to push acquisition costs down. Cencora faces especially tight negotiating room on biologics, where originator firms hold \u0026gt;80% market share and patent protection. This concentration raises margin pressure and procurement risk for Cencora.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatented drug exclusivity and pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers holding patented drugs wield huge bargaining power because no legal substitutes exist; in 2024 specialty drugs accounted for about 50% of US drug spending despite representing \u0026lt;2% of prescriptions, so Cencora must stock them regardless of price.\u003c\/p\u003e\n\u003cp\u003eThat necessity forces Cencora to accept thinner margins on high-cost therapies—some orphan and oncology treatments exceed $500,000 per patient annually—so distributors prioritize inventory completeness over margin preservation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of specialty and orphan drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to specialty and orphan drugs—51% of FDA approvals in 2023 were for biologics and rare-disease therapies—raises supplier power as manufacturers limit distributors to trusted partners. Manufacturers often appoint few distributors, tightening contract leverage and pushing up margins for chosen partners. Cencora must invest in cold-chain and specialty logistics—estimated capex rising by $200–350M through 2026—to stay preferred for these high-value suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain transparency and compliance requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturers now require end-to-end data sharing and stricter compliance across distribution, forcing Cencora to invest in IT and track-and-trace capabilities; industry surveys show 68% of pharma suppliers demanded enhanced serialization and data exchange by 2024.\u003c\/p\u003e\n\u003cp\u003eThat investment shifts tech costs to Cencora while tightening manufacturers’ control over pricing and lifecycle decisions, and failing these standards risks losing exclusive distribution contracts that drive ~40% of specialty drug revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e68% of suppliers demanded enhanced serialization by 2024\u003c\/li\u003e\n\u003cli\u003eCencora bears rising IT and compliance costs\u003c\/li\u003e\n\u003cli\u003eNoncompliance can cost exclusive contracts\u003c\/li\u003e\n\u003cli\u003eExclusive contracts drive ~40% of specialty drug revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal sourcing for generic medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWhile brand-name drug suppliers retain strong bargaining power, Cencora gains leverage in generics by sourcing globally and using competitive bidding to lower costs and dependency.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Cencora reduced generic purchase prices ~8–12% via multiple international contracts; diversify strategy limits single-supplier risk but added geopolitics in 2025 raised supplier disruption probability modestly (~+3–5%).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBrand suppliers: high power\u003c\/li\u003e\n\u003cli\u003eGenerics: leverage via global sourcing\u003c\/li\u003e\n\u003cli\u003eCompetitive bids cut prices ~8–12%\u003c\/li\u003e\n\u003cli\u003eGeopolitical risk in 2025 up ~3–5%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Soars: Brands, Specialty Drugs Drive Costs, Capex, and Disruption Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers—especially brand and biologics makers—hold high power: 60–70% of top-selling brands concentrated among few firms; specialty drugs were ~50% of US spending in 2024; exclusive contracts drive ~40% of specialty revenue. Cencora cut generic costs 8–12% by 2025 but faces ~$200–350M specialty capex and rising IT\/compliance spend; supplier-driven disruption risk rose ~3–5% in 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand concentration\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share (2024)\u003c\/td\u003e\n\u003ctd\u003e~50% spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExclusive revenue\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneric price cuts\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty capex\u003c\/td\u003e\n\u003ctd\u003e$200–$350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisruption risk ↑ (2025)\u003c\/td\u003e\n\u003ctd\u003e3–5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Cencora uncovering competitive intensity, buyer\/supplier power, threat of substitutes and entrants, and regulatory dynamics that shape pricing, margins, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Cencora—quickly identify competitive pressures and prioritize strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of healthcare providers and systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidation of US hospitals into large integrated delivery networks (IDNs) — 2024 saw 7% fewer independent hospitals and the top 25 systems now control ~40% of inpatient beds — has created massive buyers with strong negotiating leverage. These IDNs demand volume discounts and longer payment terms; a single system can represent \u0026gt;5% of a PBM’s revenue, so Cencora must match competitive pricing and add services like specialty pharmacy access and data analytics to retain them.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Pharmacy Benefit Managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePBMs decide drug formularies and reimbursement rates, directly shaping which medicines Cencora distributes and at what margin.\u003c\/p\u003e\n\u003cp\u003eBy 2025 the top three PBMs—CVS Caremark, Express Scripts (Cigna), and Optum Rx—manage roughly 75% of US commercial lives, increasing leverage to push lower reimbursement to distributors like Cencora.\u003c\/p\u003e\n\u003cp\u003eStronger PBM bargaining has compressed wholesale distribution margins; Cencora reported a 2024 gross margin of about 7.1%, reflecting pricing pressure from PBM-driven rebates and fee negotiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliance on major retail pharmacy chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant share of cencora revenue in from large retail pharmacy contracts led by walgreens boots alliance creating high customer concentration risk losing one major account could cut ebitda materially.\u003e\n\u003cp\u003eThese anchor customers wield strong leverage at renewal: they can demand lower pricing, tighter margins, or service concessions, and contract renegotiations in 2023–24 squeezed distributor margins industry-wide.\u003c\/p\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment reimbursement and policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGovernment payers like Medicare and Medicaid cover about 37% of US prescription drug spending, so federal reimbursement cuts or drug-pricing laws directly shrink pharmacy and hospital margins that buy from Cencora.\u003c\/p\u003e\n\u003cp\u003eLower government payouts force customers to negotiate harder on distributor fees and inventory terms, squeezing Cencora’s revenue per unit and raising bad-debt risk.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Congress proposals aimed at lowering drug prices and Medicare Part D reforms could reduce payer rates by an estimated 3–7% for affected drugs, amplifying customer bargaining power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicare\/Medicaid ~37% of US drug spend (2023–24)\u003c\/li\u003e\n\u003cli\u003ePotential reimbursement cuts 3–7% from 2024 reforms\u003c\/li\u003e\n\u003cli\u003eCustomers shift margin pressure to distributors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow switching costs for generic purchasing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLow switching costs in generic drug purchasing let retailers and small clinics move between distributors daily to chase price; Cencora faces this pressure despite specialty-drug barriers. In 2024 generics made up about 80% of US prescription volume but only ~20% of spend, so margins are thin and price competition is fierce. Cencora must match lower bids and faster delivery to retain volume, cutting gross-margin upside in generics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics = ~80% Rx volume, ~20% spend (US, 2024)\u003c\/li\u003e\n\u003cli\u003eRetailers routinely use multiple distributors\u003c\/li\u003e\n\u003cli\u003ePricing and delivery speed drive win rates\u003c\/li\u003e\n\u003cli\u003eCompresses Cencora’s margins on generic lines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCencora squeezed: concentrated buyers, thin margins and government\/generic pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge IDNs and three PBMs control most buying power—top 25 systems ~40% inpatient beds, top 3 PBMs ~75% commercial lives—forcing Cencora into steep discounts; 2024 gross margin ~7.1% and ~25% revenue from top retail contracts raise concentration risk. Government payers (~37% of drug spend) plus low-switching-cost generics (~80% volume, ~20% spend) keep pressure on fees and delivery terms.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 25 systems share (inpatient beds)\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 PBMs commercial lives\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCencora gross margin\u003c\/td\u003e\n\u003ctd\u003e~7.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from top retail contracts\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment share of drug spend\u003c\/td\u003e\n\u003ctd\u003e~37%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share (volume\/spend)\u003c\/td\u003e\n\u003ctd\u003e~80% \/ ~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eCencora Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Cencora Porter's Five Forces analysis you'll receive immediately after purchase—no surprises, no placeholders, fully formatted and ready for use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the part of the full version you’ll get—downloadable the moment you buy and containing the same professional content and structure as shown.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the actual deliverable; once payment is complete, you'll have instant access to this identical file for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747432411513,"sku":"cencora-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cencora-five-forces-analysis.png?v=1772198417","url":"https:\/\/growthsharematrix.com\/products\/cencora-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}